Total and Unbound Doravirine Concentrations and Viral Suppression in CSF

Juan Tiraboschi; Sofia Scévola; Sujan Dilly Penchala; Elisabeth Challenger; Laura Else; Paula Prieto; Maria Saumoy; Arkaitz Imaz; Ana Silva-Klug; Jordi Niubó; Irene Soriano; Saye Khoo; Raul Rigo-Bonin; Daniel Podzamczer

doi:10.1093/cid/ciab835

Total and Unbound Doravirine Concentrations and Viral Suppression in CSF

Clin Infect Dis. 2022 May 30;74(10):1855-1858. doi: 10.1093/cid/ciab835.

Affiliations

¹ HIV and STI Unit, Infectious Disease Service, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
² Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
³ Microbiology Service, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
⁴ Pharmacology Service, Bellvitge University Hospital, Barcelona, Spain.

PMID: 34549268
DOI: 10.1093/cid/ciab835

Abstract

We determined total and unbound concentrations of doravirine (DOR) in cerebrospinal fluid and blood plasma. Total and unbound DOR concentrations in cerebrospinal fluid exceeded the half-maximal effective concentration against wild-type virus (5.1 ng/mL) in all patients, suggesting that DOR may contribute to inhibit viral replication in this compartment.

Keywords: CNS; CSF; Doravirine; HIV; concentrations; unbound.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

HIV Infections* / drug therapy
HIV-1*
Humans
Pyridones / pharmacology
Triazoles / pharmacology
Triazoles / therapeutic use
Virus Replication

Substances

Pyridones
Triazoles
doravirine